US Patent 8,222,292: Dronabinol Oral Solution Claims, Exclusivity, Orange Book Status, and Generic Risk

US Patent 8,222,292 protects specific liquid dronabinol formulations associated with the FDA-approved product Syndros. Its strongest commercial coverage is directed to an ethanol-water-polyethylene glycol/propylene glycol system containing BHA, with specified concentration ranges, long-term stability, and reduced in vivo absorption variability. The patent does not cover dronabinol generally, Marinol capsules, or every oral cannabinoid formulation.

The patent’s nominal term is expected to run through December 2027, subject to the official patent-term calculation and any adjustment or disclaimer. Its practical value depends on whether a proposed generic uses the claimed excipient system, whether the claimed stability and pharmacokinetic limitations are met, and whether later Orange Book-listed patents create additional barriers.

What does US Patent 8,222,292 protect?

US 8,222,292 protects oral pharmaceutical solutions containing dronabinol in a defined hydroalcoholic and glycol-based vehicle. The claims focus on composition, formulation performance, and, in some claims, dosage form.

Claim	Principal subject matter	Key limitations
1	Oral dronabinol solution	30-33% water, about 50% alcohol, 5-21% co-solvent, BHA or EDTA, total composition of 100%, at least 18 months’ stability, less than 50% in vivo absorption variability
2	Narrower formulation	0.1-5% dronabinol, about 50% alcohol, 5.5% propylene glycol, 12% polyethylene glycol, 30-33% water
3	Claim 2 formulation	Alcohol is ethanol
4	Synthetic dronabinol formulation	0.1-1% synthetic dronabinol, ethanol or another alcohol at about 50%, 5.5% propylene glycol, 12% polyethylene glycol, 30-33% water, 0.01% BHA, stability and absorption limitations
5	Dosage form	Claim 4 formulation in sublingual spray form
6	Specific composition	0.54% dronabinol, 31.9% water, 12% PEG 400, 5.5% propylene glycol, 0.01% BHA, 0.05% sucralose, and 50% alcohol

The claims are formulation claims. They do not broadly claim the dronabinol molecule, the use of dronabinol for chemotherapy-induced nausea, or the treatment of AIDS-associated anorexia.

How broad is claim 1 of US 8,222,292?

Claim 1 is the broadest independent claim in the supplied claim set, but it contains several cumulative limitations.

A product must satisfy all of the following elements:

It must be an oral pharmaceutical solution.
It must contain dronabinol.
Water must account for 30-33% by weight.
Alcohol must be present at about 50% by weight.
A co-solvent must account for 5-21% by weight.
The co-solvent must be propylene glycol, polyethylene glycol, or a combination.
The antioxidant or chelating agent must be 0.01% BHA or 0.1% EDTA.
The listed components must total 100%.
The solution must be stable for at least 18 months at room or refrigerated temperature.
In vivo absorption variability must be below 50%.

The use of "consisting essentially of" narrows the permissible additional ingredients. Additional excipients may be present if they do not materially affect the basic and novel characteristics of the formulation. A generic manufacturer could therefore face infringement risk even if it adds a sweetener, flavor, preservative, or other excipient, unless that addition materially changes the claimed formulation characteristics.

The phrase "about 50%" creates a quantitative infringement issue. Courts generally interpret "about" in light of the patent specification, examples, prosecution history, and technical meaning. A formulation containing 48% or 52% ethanol cannot be assessed solely from the claim text.

What formulations are protected by claims 2 through 6?

Claims 2 through 6 progressively narrow or specify the commercial formulation.

Claims 2 and 3

Claim 2 requires:

0.1-5% dronabinol;
approximately 50% alcohol;
5.5% propylene glycol;
12% polyethylene glycol;
30-33% water.

Claim 3 limits the alcohol to ethanol. It is therefore a narrower species claim within claim 2.

The claimed formulation closely corresponds to the vehicle used for Syndros, an FDA-approved dronabinol oral solution containing 5 mg/mL dronabinol. The FDA-approved product uses alcohol, PEG 400, propylene glycol, water, BHA, and sucralose as inactive ingredients.[2]

Claims 4 and 5

Claim 4 adds synthetic dronabinol and 0.01% BHA. It also requires the stability and absorption-variability limitations.

Claim 5 adds sublingual spray form. This claim is commercially narrower than the oral-solution claims because it requires a specific delivery presentation. A conventional swallowed oral solution would not literally satisfy the sublingual-spray limitation.

Claim 6

Claim 6 recites the most commercially important composition:

0.54% dronabinol;
31.9% water;
12% PEG 400;
5.5% propylene glycol;
0.01% BHA;
0.05% sucralose;
50% alcohol.

Unlike claims 1 and 4, claim 6 as supplied does not expressly recite the 18-month stability or less-than-50% absorption-variability limitations. It also uses "comprising," which generally permits additional ingredients. That makes claim 6 potentially broader in ingredient coverage than the "consisting essentially of" claims, although its numerical formulation is more specific.

How does the patent cover Syndros?

Syndros is a 5 mg/mL dronabinol oral solution approved by the FDA under NDA 205525. The product is indicated for anorexia associated with weight loss in patients with AIDS and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.[2]

The labeled inactive ingredients include:

dehydrated alcohol;
polyethylene glycol 400;
propylene glycol;
water;
sucralose; and
butylated hydroxyanisole.[2]

Claim 6 maps closely to this formulation profile. At 5 mg/mL, a nominal 0.54% w/w dronabinol concentration is consistent with a liquid product having approximately 5 mg of dronabinol per milliliter, depending on density and manufacturing specifications.

The formulation mapping is commercially significant because an ANDA applicant seeking approval of a pharmaceutically equivalent dronabinol oral solution may need to use a similar excipient system. A formulation that departs from the claimed concentrations may avoid literal infringement but could create bioequivalence, stability, taste, solubility, or manufacturing challenges.

When does US Patent 8,222,292 lose exclusivity?

The expected nominal expiration date is December 2027, based on the patent’s underlying nonprovisional filing chronology and the 20-year U.S. patent-term rule. The exact enforceable term must be determined from the USPTO patent-term calculation, including any patent-term adjustment, patent-term extension, terminal disclaimer, or other statutory modification.[1]

Milestone	Date or status
Patent	US 8,222,292
Issue date	July 17, 2012
Technology	Dronabinol oral pharmaceutical solutions
FDA product associated with formulation	Syndros, NDA 205525
FDA approval of Syndros	July 28, 2016
Nominal patent expiration	December 2027
Three-year regulatory exclusivity for new dosage form	Expired in 2019
Small-molecule regulatory pathway	ANDA, not biosimilar pathway

FDA regulatory exclusivity and patent exclusivity are separate. The approval of Syndros generated regulatory exclusivity associated with the new dosage form, but that period did not extend through the expected patent expiration. A generic applicant may have been able to file an ANDA after the applicable exclusivity period ended, subject to patent certification requirements.

What is the Orange Book status of the dronabinol oral solution?

Syndros is an NDA product listed in the FDA Orange Book. Patent listings for an NDA product provide the patent numbers and, where applicable, use codes that may affect ANDA certification and labeling.[3]

The relevant commercial distinction is:

Orange Book listing creates a patent-certification issue for an ANDA applicant.
It does not independently establish patent validity.
It does not prove that every generic formulation infringes.
A listed patent may be challenged through a Paragraph IV certification.
A successful Paragraph IV notice can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework.[4]

The formulation claims in US 8,222,292 are more likely to present a composition-based Paragraph IV issue than a method-of-use issue. An ANDA applicant could argue that its formulation falls outside the claimed percentage ranges, uses a different solvent system, does not contain BHA or EDTA at the claimed level, or does not meet the claimed pharmacokinetic limitation.

What Paragraph IV challenges and litigation affect US 8,222,292?

The supplied claims do not identify a Paragraph IV notice, ANDA number, court case, settlement, or launch agreement. The patent itself therefore cannot establish the existence or outcome of a particular challenge.

For a challenger, the principal litigation positions would likely include:

Challenge theory	Potential target
Non-infringement	Water, alcohol, glycol, BHA, EDTA, or dronabinol concentration outside claim scope
Non-infringement	Product lacks the claimed 18-month stability or absorption-variability profile
Non-infringement	Product is not a sublingual spray for claim 5
Invalidity for anticipation	Earlier dronabinol liquid formulation discloses all claim elements
Invalidity for obviousness	Combination of known dronabinol solubilization vehicles and conventional antioxidants or chelators
Indefiniteness	Meaning of "about," "stable," "room or refrigerated temperatures," or "absorption variability"
Written-description or enablement challenge	Breadth of the co-solvent and performance limitations in claim 1

The stability and pharmacokinetic limitations may strengthen validity if supported by comparative data, but they also create proof issues. The patent owner would need to show that the accused product meets those limitations. A generic applicant may attempt to avoid the limitation by controlling the formulation or by contesting whether the limitation is inherent in its product.

How strong is the patent estate for dronabinol oral solution?

The patent estate is strongest against a generic that copies the Syndros vehicle. It is weaker against alternative liquid formulations using different solvent ratios, different antioxidants, non-glycol co-solvents, or a different dosage form.

Strengths

Claim 6 targets a commercially recognizable formulation.
Claims 2-4 cover the principal ethanol, PEG 400, propylene glycol, water, and BHA system.
The claims include measurable concentration ranges.
Stability and absorption-variability limitations may reflect formulation-performance advantages.
The patent covers a solution rather than only a manufacturing process.

Weaknesses

The composition uses conventional pharmaceutical excipients.
Dronabinol oral liquids and hydroalcoholic vehicles were known before the patent’s priority date.
"About 50%" and other functional terms may require fact-intensive construction.
Claim 1’s "consisting essentially of" language limits permissible formulation variations.
A generic manufacturer may design around the specific BHA, EDTA, solvent, or concentration requirements.
Claim 6’s exact quantitative requirements may create vulnerability if prior art discloses a materially similar formulation.

The patent’s commercial strength is therefore formulation-specific rather than molecule-wide.

How does US 8,222,292 compare with Marinol patents?

Marinol contains dronabinol in capsule form, while Syndros is an oral solution. The two products have different formulation and administration profiles.

Factor	Marinol	Syndros
Active ingredient	Dronabinol	Dronabinol
Dosage form	Oral capsule	Oral solution
Primary formulation issue	Sesame-oil capsule system	Hydroalcoholic PEG/propylene glycol solution
Patent relevance	Earlier dronabinol capsule and use patents	US 8,222,292 formulation claims
Generic pathway	ANDA	ANDA
Biosimilar pathway	Not applicable	Not applicable
Main design-around opportunity	Different capsule formulation	Alternative liquid vehicle or dosage form

Earlier dronabinol molecule and capsule patents do not automatically anticipate or invalidate the claimed oral solution. Anticipation requires a single prior-art reference to disclose every claim element arranged as claimed.[5]

Are biosimilar risks relevant to dronabinol?

No. Dronabinol is a chemically synthesized small molecule, not a biologic. A competing product would generally use the abbreviated new drug application pathway rather than the biosimilar pathway under the Public Health Service Act.

The relevant competitive risks are:

ANDA approval;
Paragraph IV patent challenges;
authorized generic entry;
formulation design-arounds;
alternative oral dosage forms; and
compounded or non-equivalent cannabinoid products.

FDA approval of a generic oral solution would require pharmaceutical equivalence and bioequivalence to the applicable reference product, subject to the product-specific guidance and FDA review requirements.[6]

What generic launch scenarios exist?

Scenario 1: Copy formulation

A generic closely matching the Syndros formulation would face the highest infringement exposure under claims 2, 3, 4, and 6. The applicant would likely need a Paragraph IV position or a launch date after patent expiry.

Scenario 2: Concentration design-around

A manufacturer could alter the water, ethanol, PEG 400, or propylene glycol concentrations. This may avoid literal infringement, but the product would still need to demonstrate adequate solubility, shelf life, taste, dose uniformity, and bioequivalence.

Scenario 3: Antioxidant design-around

Replacing BHA with another antioxidant may avoid claims requiring 0.01% BHA. It would not necessarily avoid claim 1 if the formulation uses 0.1% EDTA or falls within another claimed alternative.

Scenario 4: Different dosage form

A capsule, tablet, emulsion, or non-solution liquid would have a stronger design-around position against the solution claims. It may, however, be less substitutable for patients requiring the liquid product.

Scenario 5: Post-expiration entry

Entry after expiration would remove the principal barrier created by US 8,222,292, subject to any later-expiring formulation, method-of-use, or manufacturing patents listed for the reference product.

What manufacturing and IP barriers remain?

The patent does not claim a manufacturing process in the supplied claims. The principal barrier is therefore the formulation itself, not a protected synthesis route or filling process.

Commercial barriers may remain even after patent expiry:

maintaining dronabinol solubility in a high-alcohol vehicle;
controlling evaporation and fill-volume variation;
preserving stability over the labeled shelf life;
managing packaging compatibility;
reproducing taste and dose uniformity;
demonstrating bioequivalence for a liquid product; and
complying with controlled-substance manufacturing and distribution requirements.

These barriers can slow entry without extending patent rights.

Key Takeaways

US 8,222,292 is a formulation patent for dronabinol oral solutions, not a patent on dronabinol generally.
The core claimed vehicle contains approximately 50% alcohol, 30-33% water, PEG, propylene glycol, and BHA or EDTA.
Claim 6 closely tracks the commercial Syndros formulation, including PEG 400, propylene glycol, BHA, sucralose, and 0.54% dronabinol.
Claims 1 and 4 add stability and absorption-variability limitations that may create both validity support and infringement-proof issues.
The patent’s nominal expiration is expected in December 2027.
Dronabinol is a small molecule, so biosimilar analysis is not applicable.
Generic risk centers on ANDA approval, Paragraph IV certification, formulation design-arounds, and later-listed patents.
A generic copying the Syndros excipient system presents materially higher infringement risk than an alternative liquid or non-solution dosage form.
The supplied claim set does not establish a specific Paragraph IV lawsuit, settlement, or authorized launch date.

FAQs

Can a generic avoid US 8,222,292 by using a different percentage of ethanol?

Potentially. A material change outside the claim’s quantitative limitations may avoid literal infringement, but the result depends on the construction of "about 50%" and any applicable doctrine-of-equivalents analysis.

Does claim 6 require the product to contain sucralose?

Yes. The supplied claim 6 expressly recites 0.05% sucralose. Because the claim uses "comprising," additional ingredients may be permitted, but omission of sucralose would create a non-infringement position for that claim.

Does US 8,222,292 cover synthetic dronabinol only?

No. Claim 4 expressly requires synthetic dronabinol, but claims 1-3 and 6, as supplied, do not contain the same synthetic-source limitation.

Can a capsule generic infringe this patent?

A capsule would generally have a strong non-infringement position against claims requiring an oral pharmaceutical solution. Other patents, including dosage-form or method-of-use patents, would require separate analysis.

Is the less-than-50% absorption-variability limitation present in every claim?

No. It appears in claims 1 and 4 as supplied. It does not appear expressly in claims 2, 3, 5, or 6 unless incorporated through claim dependency, and claims 2-6 are presented as separate claims in the supplied text.

References

United States Patent No. 8,222,292. (2012). Pharmaceutical compositions comprising dronabinol. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2023). Syndros (dronabinol) oral solution prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
35 U.S.C. §§ 102, 103, 112.
U.S. Food and Drug Administration. (2024). Product-specific guidance for generic drug development.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Wellhouse Pharma	SYNDROS	dronabinol	SOLUTION;ORAL	205525-001	Mar 23, 2017		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial	Y	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2698752	⤷ Start Trial
European Patent Office	2184983	⤷ Start Trial
Japan	2010535774	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2009020666	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,222,292

Which drugs does patent 8,222,292 protect, and when does it expire?

Summary for Patent: 8,222,292